The SPA17-AXL axis drives melanoma aggressiveness and SPA17-targeting vaccination exhibits antitumor efficacy.

Zhang L, You M, Yan B, Zhang J, Yao Y, Zhang Q, Xie Z, Wang S, Gao Q

Open source

DOI
10.3389/fimmu.2026.1914680
Published
2026
Container
Frontiers in immunology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1914680,
  title = {The SPA17-AXL axis drives melanoma aggressiveness and SPA17-targeting vaccination exhibits antitumor efficacy.},
  author = {Zhang L and You M and Yan B and Zhang J and Yao Y and Zhang Q and Xie Z and Wang S and Gao Q},
  year = {2026},
  journal = {Frontiers in immunology},
  doi = {10.3389/fimmu.2026.1914680},
  url = {https://doi.org/10.3389/fimmu.2026.1914680}
}

RIS

TY  - JOUR
TI  - The SPA17-AXL axis drives melanoma aggressiveness and SPA17-targeting vaccination exhibits antitumor efficacy.
AU  - Zhang L
AU  - You M
AU  - Yan B
AU  - Zhang J
AU  - Yao Y
AU  - Zhang Q
AU  - Xie Z
AU  - Wang S
AU  - Gao Q
PY  - 2026
JO  - Frontiers in immunology
DO  - 10.3389/fimmu.2026.1914680
UR  - https://doi.org/10.3389/fimmu.2026.1914680
ER  - 

APA

L, Z., M, Y., B, Y., J, Z., Y, Y., Q, Z., Z, X., S, W., & Q, G. (2026). The SPA17-AXL axis drives melanoma aggressiveness and SPA17-targeting vaccination exhibits antitumor efficacy.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1914680

Source records